 Cyclerion Therapeutics Inc NASDAQ: CYCN and Beacon Biosignals have expanded strategic partnerships between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerions CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment. 